Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:59 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 20,623 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Terminated Phase 1 Interventional

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

NCT02012231
View directory record Official record
Conditions
Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Histiocytosis, Hairy Cell Leukemia
Interventions
PLX8394
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Nov 2, 2026, 2:59 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

BREATHE-Peds Pilot- II III Trial and Post Trial

NCT05832437
View directory record Official record
Conditions
Asthma in Children
Interventions
BREATHE-Peds Intervention, Control Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 14 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

NCT02052141
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CINRYZE 500, CINRYZE 1000
Biological
Lead sponsor
Shire
Industry
Eligibility
6 Years to 11 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Colorado Springs, Colorado • Las Vegas, Nevada • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Nov 2, 2026, 2:59 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

NCT06704269
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
YTB323
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Orange, California • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 2 Interventional Results available

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

NCT01234766
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Bendamustine, Rituximab, Y-90 ibritumomab
Drug · Radiation
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
4
States / cities
Scarborough, Maine • Lebanon, New Hampshire • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 2, 2026, 2:59 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients

NCT00481637
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

NCT00017472
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
apolizumab, laboratory biomarker analysis, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Nov 2, 2026, 2:59 AM EST
Terminated Phase 2 Interventional Results available

Lenalidomide Maintenance Therapy for Multiple Myeloma

NCT01675141
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 2, 2026, 2:59 AM EST
Active, not recruiting Phase 3 Interventional

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 1 Interventional

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

NCT01831505
View directory record Official record
Conditions
Lymphoma
Interventions
Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them
Drug
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Nov 2, 2026, 2:59 AM EST
Withdrawn Early Phase 1 Interventional

Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries

NCT02959294
View directory record Official record
Conditions
Traumatic Encephalopathies, Chronic, Concussion, Mild, Concussion, Intermediate, Concussion, Severe, Concussion, Brain
Interventions
Microcannula Harvest Adipose, Centricyte 1000, Sterile Normal Saline IV deployment AD-cSVF
Procedure · Device
Lead sponsor
Robert W. Alexander, MD, FICS
Industry
Eligibility
16 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Nov 2, 2026, 2:59 AM EST
Terminated Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

NCT00281294
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Fontolizumab
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 2, 2026, 2:59 AM EST
Completed Not applicable Interventional

A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back Pain

NCT02707094
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Biomodulator, Usual Care (Medication + Exercise)
Device · Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 62 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 2 Interventional

Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis

NCT00000429
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Calcium carbonate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 1Phase 2 Interventional Results available

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

NCT01827137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Galinpepimut-S, GM-CSF, Montanide, lenalidomide, bortezomib
Biological · Other · Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 2 Interventional Results available

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

NCT01000506
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 750, Mepolizumab 250, Mepolizumab 75, Placebo saline
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Riverside, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 1Phase 2 Interventional Results available

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

NCT02304458
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 30 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting

NCT01638299
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypo-Hyper Minimizer (HHM) System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Nov 2, 2026, 2:59 AM EST
Recruiting Phase 1 Interventional

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

NCT07444632
View directory record Official record
Conditions
Lymphoid, Hodgkin Lymphoma
Interventions
Fludarabine, TGFBR2 KO CAR27/IL-15 NK cells, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 2, 2026, 2:59 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

NCT02665221
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
No Treatment Arm, Topical Preparation H arm
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Nov 2, 2026, 2:59 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Experience of Having Chronic Graft-Versus-Host Disease

NCT00353106
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Interview, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
2
States / cities
Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Nov 2, 2026, 2:59 AM EST
Completed Phase 2 Interventional

Dehydroepiandrosterone Effects on HIV-1 Replication

NCT00065104
View directory record Official record
Conditions
HIV Infections
Interventions
DHEA
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Nov 2, 2026, 2:59 AM EST
Active, not recruiting No phase listed Observational

Characterizing Sleep Among Long-term Survivors of Childhood Cancer

NCT05480904
View directory record Official record
Conditions
ALL, Adult, CNS Tumor, Solid Tumor
Interventions
Neurocognitive (Thinking) Testing, CNS Vital Signs (Thinking) Testing, Health Questionnaires, Sleep Surveys & Sleep Diary, Echocardiography/EKG, Pulmonary Function, Remote Polysomnography, Physical Function
Other · Diagnostic Test · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 2, 2026, 2:59 AM EST